TTM
$15.57B
YoY change
+26.5%
5Y CAGR
+5.4%
Peak year (2025)
$16.90B
Cumulative EBITDA
$235.98B
EBITDA history chart for Amgen (AMGN) from 1985 to 2025
Latest: $16.90B
EBITDA growth chart for Amgen (AMGN) from 1985 to 2025
Latest: +26.5%
EBITDA history table for Amgen (AMGN) from 1985 to 2025
| 2025 | $16.90B | +26.5% | +$3.54B | ||
| 2024 | $13.36B | -9.8% | −$1.45B | ||
| 2023 | $14.80B | +21.6% | +$2.63B | ||
| 2022 | $12.17B | +7.7% | +$873.00M | ||
| 2021 | $11.30B | -13.1% | −$1.70B | ||
| 2020 | $13.00B | +2.9% | +$363.00M | ||
| 2019 | $12.63B | -1.9% | −$250.00M | ||
| 2018 | $12.88B | +0.2% | +$27.00M | ||
| 2017 | $12.86B | +2.6% | +$328.00M | ||
| 2016 | $12.53B | +12.0% | +$1.35B | ||
| 2015 | $11.18B | +27.8% | +$2.43B | ||
| 2014 | $8.75B | +15.5% | +$1.18B | ||
| 2013 | $7.57B | +5.9% | +$423.00M | ||
| 2012 | $7.15B | +22.9% | +$1.33B | ||
| 2011 | $5.82B | -16.1% | −$1.12B | ||
| 2010 | $6.94B | +1.6% | +$107.00M | ||
| 2009 | $6.83B | +2.9% | +$192.00M | ||
| 2008 | $6.64B | +11.0% | +$658.00M | ||
| 2007 | $5.98B | -0.9% | −$53.00M | ||
| 2006 | $6.03B | +6.1% | +$345.00M | ||
| 2005 | $5.69B | +22.7% | +$1.05B | ||
| 2004 | $4.64B | +22.7% | +$858.00M | ||
| 2003 | $3.78B | +42.4% | +$1.12B | ||
| 2002 | $2.65B | +47.7% | +$856.90M | ||
| 2001 | $1.80B | +13.7% | +$217.20M | ||
| 2000 | $1.58B | +5.2% | +$78.10M | ||
| 1999 | $1.50B | +19.0% | +$239.60M | ||
| 1998 | $1.26B | +20.5% | +$214.80M | ||
| 1997 | $1.05B | +3.1% | +$31.10M | ||
| 1996 | $1.02B | +20.3% | +$171.30M | ||
| 1995 | $845.00M | +9.3% | +$72.00M | ||
| 1994 | $773.00M | +28.4% | +$171.10M | ||
| 1993 | $601.90M | +13.2% | +$70.20M | ||
| 1992 | $531.70M | +266.9% | +$386.80M | ||
| 1991 | $144.90M | +110.6% | +$76.10M | ||
| 1990 | $68.80M | — | — | ||
| 1988 | $3.20M | -313.3% | +$4.70M | ||
| 1987 | −$1.50M | -225.0% | −$2.70M | ||
| 1986 | $1.20M | -25.0% | −$400.00K | ||
| 1985 | $1.60M | — | — |
- 2025$16.90B+26.5%
- 2024$13.36B-9.8%
- 2023$14.80B+21.6%
- 2022$12.17B+7.7%
- 2021$11.30B-13.1%
- 2020$13.00B+2.9%
- 2019$12.63B-1.9%
- 2018$12.88B+0.2%
- 2017$12.86B+2.6%
- 2016$12.53B+12.0%
- 2015$11.18B+27.8%
- 2014$8.75B+15.5%
- 2013$7.57B+5.9%
- 2012$7.15B+22.9%
- 2011$5.82B-16.1%
- 2010$6.94B+1.6%
- 2009$6.83B+2.9%
- 2008$6.64B+11.0%
- 2007$5.98B-0.9%
- 2006$6.03B+6.1%
- 2005$5.69B+22.7%
- 2004$4.64B+22.7%
- 2003$3.78B+42.4%
- 2002$2.65B+47.7%
- 2001$1.80B+13.7%
- 2000$1.58B+5.2%
- 1999$1.50B+19.0%
- 1998$1.26B+20.5%
- 1997$1.05B+3.1%
- 1996$1.02B+20.3%
- 1995$845.00M+9.3%
- 1994$773.00M+28.4%
- 1993$601.90M+13.2%
- 1992$531.70M+266.9%
- 1991$144.90M+110.6%
- 1990$68.80M—
- 1988$3.20M-313.3%
- 1987−$1.50M-225.0%
- 1986$1.20M-25.0%
- 1985$1.60M—
EBITDA values are taken from Amgen's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EBITDA at Amgen (AMGN)
According to Amgen's latest reported financial statements, the company's current EBITDA (TTM) is $15.57B. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Amgen (AMGN) most recent annual EBITDA stands at $16.90B (2025) – grew 26.5% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Amgen EBITDA compounded at +5.4% per year, with mixed annual results across the window.
Across the available history, EBITDA reached its high of $16.90B in 2025 and its low of −$1.50M in 1987.
Amgen EBITDA by Year
Amgen EBITDA 2025: $16.90B
Amgen posted EBITDA of $16.90B in 2025, grew 26.5% from 2024. This figure represents the highest annual value in the available history.
Amgen EBITDA 2024: $13.36B
In 2024, Amgen reported EBITDA of $13.36B, declined 9.8% below 2023.
Amgen EBITDA 2023: $14.80B
Amgen EBITDA in 2023 was $14.80B, grew 21.6% from 2022.
Amgen EBITDA 2022: $12.17B
2022's EBITDA for Amgen came in at $12.17B, grew 7.7% from 2021.
Amgen EBITDA 2021: $11.30B
Amgen EBITDA in 2021 was $11.30B.
See more financial history for Amgen (AMGN).
Sector peers by EBITDA
Healthcare peers of Amgen (AMGN), ranked by their latest EBITDA
| $41.05B | |
| $28.26B | |
| $27.94B | |
| $24.43B | |
| $23.06B | |
| $19.83B | |
| $17.63B | |
| $11.47B |
- $41.05B
- $28.26B
- $27.94B
- $24.43B
- $23.06B
- $19.83B
- $17.63B
Frequently asked questions
Amgen (AMGN) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation